Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer-Reference-Cited by-同舟云学术

Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer

Published:2019-01-14 Issue:2 Volume:129 Page:759-773
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Ding Yufeng,Li Ni,Dong Baijun,Guo Wangxin,Wei Hui,Chen Qilong,Yuan Huairui,Han Ying,Chang Hanwen,Kan Shan,Wang Xuege,Pan Qiang,Wu Ping,Peng Chao,Qiu Tong,Li Qintong^ORCID,Gao Dong,Xue Wei,Qin Jun^ORCID

Funder

National Key research and Development Program of China

the Chinese Academy of Sciences

the Strategic Priority Research Program of the Chinese Academy of Sciences

the National Natural Science Foundation of China

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/123557/files/pdf

Reference67 articles.

1. Molecular genetics of prostate cancer: new prospects for old challenges

2. Integrative Clinical Genomics of Advanced Prostate Cancer

3. Integrative Genomic Profiling of Human Prostate Cancer

4. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer

5. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRG1 promotes liver cancer cell proliferation and metastasis by enhancing mitochondrial function and ATP5A1 synthesis through TOMM40;Cancer Biology & Therapy;2024-07-08

2. Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos;2024-06-09

3. SMARCA4 (BRG1) activates ABCC3 transcription to promote hepatocellular carcinogenesis;Life Sciences;2024-06

4. The therapeutic potential of targeting the CHD protein family in cancer;Pharmacology & Therapeutics;2024-04

5. Androgen receptor-negative prostate cancer is vulnerable to SWI/SNF-targeting degrader molecules;2024-03-27